Clinical Trial

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-04.
Status change: Not Yet Recruiting → Recruiting 2025-08-31
Trial Details
NCT Number NCT07065968
Lead Sponsor Peking University People's Hospital
Collaborators: Peking University Health Science Center, Cisen Pharmaceutical CO., LTD.
Conditions Immune Thrombocytopenia (ITP)
Enrollment 132 participants
Start Date 2025-08-19
Primary Completion 2027-09-10 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-08